ACE inhibitors or ARBs are the preferred first-line agent for hypertension treatment among patients with diabetes and UACR ≥300 mg/g because of their proven benefits for the prevention of CKD progression [54]. The gene discussed is ACE; the disease is chronic kidney disease.